drugset / Trial / NCT06895486
Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation
Phase 2
Recruiting
675 enrolled
PATH
Bill and Melinda Gates Foundation · collabCenters for Disease Control and Prevention · collabCentro de Vacunación e Investigación (Cevaxin) · collabPT Bio Farma · collabTechnical Resources International, Inc. · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The purpose of this study is to evaluate the safety and tolerability of co-administration of nOPV1 + nOPV2 in infants, relative to those receiving monovalent nOPV vaccines alone and whether two and/or three doses of co-administered nOPV1 and nOPV2 are non-inferior to corresponding doses of nOPV1 alone and nOPV2 alone.
Timeline
- Start
- 2025-11-11
- Primary completion
- 2026-12-28
- Completion
- 2026-12-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | nOPV1 | Vaccine | 1e+07 unknown | Oral |
| Subject | nOPV2 | Vaccine | 100000 unknown | Oral |